Figures computed from official regulatory filings — .
Analysttarget 17.75 USD (+2184%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 12.34% · institutions 12.89% · short 0.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for REVELATION BIOSCIENCES, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
10 buys10 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Zygmont Chester Stanley III | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zygmont Chester Stanley III | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CARVER JENNIFER | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zygmont Chester Stanley III | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ROPER JESS | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chawla Lakhmir S | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rolke James | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rolke James | Other | $11.4K | SEC |
| Zygmont Chester Stanley III | Other | $14.6K | SEC |
| Chawla Lakhmir S | Other | $4.2K | SEC |
| Zygmont Chester Stanley III | Other | $21.6K | SEC |
| ROPER JESS | Other | $2.9K | SEC |
| Rolke James | Other | $15.8K | SEC |
| CARVER JENNIFER | Other | $3.1K | SEC |
| CARVER JENNIFER | Award | $37.8K | Unusual size | SEC |
| Rolke James | Award | $479.5K | Unusual size | SEC |
| Chawla Lakhmir S | Award | $37.8K | Unusual size | SEC |
| ROPER JESS | Award | $37.8K | Unusual size | SEC |
| Zygmont Chester Stanley III | Award | $70.3K | SEC |
| Chawla Lakhmir S | Award | $20K | Unusual size | SEC |
| CARVER JENNIFER | Award | $20K | Unusual size | SEC |
| Zygmont Chester Stanley III | Award | $500K | SEC |
| Rolke James | Award | $500K | Unusual size | SEC |
| ROPER JESS | Award | $20K | Unusual size | SEC |
| TIDMARSH GEORGE Ftrack record | Award | $700.5 | SEC |